Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients

Compass shares rose 3% after the London-based mental-health care group reported in a follow-up study that its COMP360 psilocybin treatment, alongside psychological support, led to remission of depression in most cancer patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.